



Press Release / Press Release

For Immediate Release

**CYTOMICS SYSTEMS CHANGES ITS NAME TO CYTOMICS
PHARMACEUTICALS**

The privately-held development-stage company with proprietary expertise in protein degradation pathways relocates into a state of the art facility within the "Orsay Park".

Orsay (France) – February 20th, 2008 - CYTOMICS SYSTEMS, a privately-held development-stage company with proprietary expertise in protein degradation pathways, today announced that it has changed its corporate name to CYTOMICS PHARMACEUTICALS. This new name better reflects the advancement of its research programs.

Bernard Cambou, Ph.D., Chairman of the Management Board, declared: *"This new name better reflects what our Company is about. Today, we are progressing well to bring to human clinical trials new chemical entities associated with novel mechanisms of action in the anti-cancer and anti-fungal areas."*

Moreover, the new name of the Company corresponds to another major step in its history. Originally located within the CNRS campus in Gif-sur-Yvette, CYTOMICS PHARMACEUTICALS announced that it has just completed its relocation into a new 10,000 sqf facility within the "ORSAY PARK" in Orsay. Thanks to this new facility the Company has more than quadruple its lab space. This will allow to internalize most of the activities as the Company needed to increase its medicinal chemistry and cellular biology capabilities to accommodate the growing requirements of its various programs.

Erwan Martin, CFO of the Company and a member of the Management Board who led the site search and remodeling added *"We conducted a wide search within the Paris region and based upon various pre-determined criteria we spotted "ORSAY PARK" as a unique opportunity to provide us with a technology-friendly environment that is logistically well-situated to retain and attract the talent that we so much need in the conduct of our activities."*

About CYTOMICS PHARMACEUTICALS

CYTOMICS PHARMACEUTICALS founded in 2000 is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases such as cancer and fungal infections. The Company was founded by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics, and internationally recognized for his work in the field of the Ubiquitin-Proteasome pathway for protein degradation.

The Company has developed an innovative high-throughput screening technology, *UbiScreen™*, for the discovery of new therapeutic molecules controlling the degradation of target proteins. CYTOMICS PHARMACEUTICALS has used this technology to target cancers and fungal infections with compounds at the preclinical stage.

Cytomics Pharmaceuticals (www.cytomics.fr) is now based in Orsay (France).

Contacts

CYTOMICS PHARMACEUTICALS

Erwan MARTIN, CFO

Tél. : +33 (0)1 69 18 72 08

E-mail : emartin@cytomics.fr

MILESTONES – Press Relations

Bruno ARABIAN –

Tél. : +33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26

E-mail : milestones@milestones-fr.com